Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This halts the growth of rapidly dividing cells and also reduces inflammatory activity by affecting immune cell function.

The dose of Methofill is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Only a qualified health professional should determine the appropriate regimen.

Methofill is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while receiving treatment.

To order Methofill, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with biologic DMARDs such as adalimumab, methotrexate (Methofill) is an oral/injectable small‑molecule agent that is less expensive and has a well‑established safety profile, but it may be less rapid in controlling severe disease. In oncology, it offers a different mechanism than agents like cyclophosphamide, providing a folate‑antagonist approach.

Methofill should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Methofill is supplied for subcutaneous injection. The healthcare professional prepares the dose using aseptic technique, selects an appropriate injection site (typically the abdomen or thigh), and administers the medication at a 45‑degree angle after cleaning the skin with an alcohol swab.

Serious adverse events include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, acute renal failure, and rare secondary malignancies. Patients should be monitored regularly for signs of hepatic dysfunction, respiratory symptoms, and abnormal blood counts.

Methofill is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing lung disease.